RxDoctor Payments Data

Robert McCord, MD

Internal Medicine · River Ridge, LANPI 1730264920

Payments from drug & device makers

$4,935in general payments, 2019–2025

Across 282 payments — averaging $17.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • AstraZeneca$585
  • Novo Nordisk$506
  • Pfizer$488
  • Lilly USA, LLC$377
  • Boehringer Ingelheim$156
  • plus $1K from 32 others

What the payments were for

  • Food & beverage$4,935100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,935 in reported general payments places this provider in the 85th percentile of 1,528 internal medicine providers in Louisiana.

See all internal medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$39,102
Medicare patients
116
Services billed
439

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide77$79,806
EliquisApixaban73$70,971
JardianceEmpagliflozin42$57,159
Nurtec OdtRimegepant Sulfate18$23,056
JanuviaSitagliptin Phosphate18$22,323
TradjentaLinagliptin12$18,377
FarxigaDapagliflozin Propanediol25$17,665
RelistorMethylnaltrexone Bromide18$17,408
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$14,959
Repatha SureclickEvolocumab16$13,784
MounjaroTirzepatide12$12,902
Breztri AerosphereBudesonide/Glycopyr/Formoterol12$7,306
Gabapentin195$4,215
Dexlansoprazole DrDexlansoprazole24$4,212
Bupropion XlBupropion Hcl115$3,438

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Nurtec Odt$488$94,02691 claims
Novo NordiskOzempic$506$79,80677 claims
Boehringer IngelheimJardiance, Tradjenta$156$75,53754 claims
AstraZenecaFarxiga, Breztri Aerosphere$585$24,97137 claims
MerckJanuvia$134$22,32318 claims
GSKTrelegy Ellipta$49$14,95915 claims
Lilly USA, LLCMounjaro$377$12,90212 claims
AbbVieSynthroid$1,462$1,52930 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,528 internal medicine providers in Louisiana.

Other internal medicine in River Ridge

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →